![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: SLC16A12 |
Gene summary for SLC16A12 |
![]() |
Gene information | Species | Human | Gene symbol | SLC16A12 | Gene ID | 387700 |
Gene name | solute carrier family 16 member 12 | |
Gene Alias | CJMG | |
Cytomap | 10q23.31 | |
Gene Type | protein-coding | GO ID | GO:0003008 | UniProtAcc | E9PSF9 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
387700 | SLC16A12 | HCC1 | Human | Liver | HCC | 1.17e-09 | 8.93e-01 | 0.5336 |
387700 | SLC16A12 | HCC2 | Human | Liver | HCC | 1.12e-12 | 8.60e-01 | 0.5341 |
387700 | SLC16A12 | HCC5 | Human | Liver | HCC | 8.95e-17 | 9.43e-01 | 0.4932 |
387700 | SLC16A12 | Pt13.b | Human | Liver | HCC | 2.19e-03 | 1.03e-01 | 0.0251 |
387700 | SLC16A12 | S027 | Human | Liver | HCC | 7.33e-06 | 3.89e-01 | 0.2446 |
387700 | SLC16A12 | S028 | Human | Liver | HCC | 1.37e-24 | 6.73e-01 | 0.2503 |
387700 | SLC16A12 | S029 | Human | Liver | HCC | 2.15e-13 | 4.37e-01 | 0.2581 |
387700 | SLC16A12 | HTA12-26-1 | Human | Pancreas | PDAC | 1.14e-13 | 9.08e-01 | 0.3728 |
387700 | SLC16A12 | HTA12-29-1 | Human | Pancreas | PDAC | 2.51e-17 | 6.53e-01 | 0.3722 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:015010411 | Liver | HCC | transport across blood-brain barrier | 50/7958 | 87/18723 | 3.42e-03 | 1.55e-02 | 50 |
GO:001023211 | Liver | HCC | vascular transport | 50/7958 | 88/18723 | 4.69e-03 | 2.02e-02 | 50 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SLC16A12 | SNV | Missense_Mutation | c.547A>G | p.Ser183Gly | p.S183G | protein_coding | deleterious(0.01) | probably_damaging(0.955) | TCGA-AN-A04D-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
SLC16A12 | SNV | Missense_Mutation | c.1226N>T | p.Ser409Leu | p.S409L | protein_coding | deleterious(0.01) | probably_damaging(0.97) | TCGA-E2-A1B1-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Other, specify in notesbiphosphonate | zoledronic | SD | ||
SLC16A12 | insertion | Frame_Shift_Ins | novel | c.945_946insAAGGCACCAAGTACACAAAGAGAGGGCTG | p.Gln316LysfsTer22 | p.Q316Kfs*22 | protein_coding | TCGA-A7-A0CE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |||
SLC16A12 | deletion | Frame_Shift_Del | novel | c.1220delT | p.Leu407CysfsTer18 | p.L407Cfs*18 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |||
SLC16A12 | SNV | Missense_Mutation | novel | c.898C>G | p.Leu300Val | p.L300V | protein_coding | tolerated(0.19) | benign(0.015) | TCGA-VS-A9U7-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
SLC16A12 | SNV | Missense_Mutation | novel | c.211N>T | p.Ile71Phe | p.I71F | protein_coding | tolerated(0.08) | benign(0.059) | TCGA-A6-2686-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
SLC16A12 | SNV | Missense_Mutation | rs551632763 | c.253N>A | p.Ala85Thr | p.A85T | protein_coding | tolerated(0.33) | possibly_damaging(0.461) | TCGA-A6-4105-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
SLC16A12 | SNV | Missense_Mutation | c.1093N>A | p.Leu365Ile | p.L365I | protein_coding | deleterious(0.02) | possibly_damaging(0.869) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | ||
SLC16A12 | SNV | Missense_Mutation | c.308N>A | p.Pro103Gln | p.P103Q | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | ||
SLC16A12 | SNV | Missense_Mutation | c.1193N>T | p.Thr398Ile | p.T398I | protein_coding | tolerated(0.27) | possibly_damaging(0.795) | TCGA-D5-6928-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |